Literature DB >> 6848402

Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.

Y F Liaw, C M Chu, I J Su, M J Huang, D Y Lin, C S Chang-Chien.   

Abstract

A 60-mo longitudinal study has been undertaken in 99 HBeAg-positive patients with clinicopathologically verified chronic hepatitis. Hepatitis B e antigen clearance occurred in 30 patients at a rate of approximately 17% per year. A phenomenon of abrupt elevation of serum glutamic pyruvic transaminase (greater than 300 IU/L) with histological changes compatible with chronic lobular hepatitis was observed in 13 of 20 patients (65%) preceding spontaneous HBeAg clearance. In contrast, 8 of 10 patients on immunosuppressive or antiviral therapy, or both, had uneventful HBeAg clearance. It was concluded that HBeAg clearance can occur in patients with varying immunologic status. The mechanism responsible for HBeAg clearance awaits further study.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848402

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  54 in total

Review 1.  Hepatitis B therapy.

Authors:  Hellan Kwon; Anna S Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  High level of hepatitis B virus DNA after HBeAg-to-anti-HBe seroconversion is related to coexistence of mutations in its precore and basal core promoter.

Authors:  Xiao-Mou Peng; Gui-Mei Huang; Jian-Guo Li; Yang-Su Huang; Yong-Yu Mei; Zhi-Liang Gao
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

3.  A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective.

Authors:  Sarah E Post; Neetu Khurana Sodhi; Chia-Hui Peng; Kejia Wan; Henry J Pollack
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

4.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

5.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

6.  Occurrence of hepatocellular carcinoma in chronic viral hepatitis.

Authors:  M Omata; S Takano
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Authors:  Mayur Brahmania; Manuel Lombardero; Bettina E Hansen; Norah A Terrault; Anna S Lok; Robert P Perrillo; Steven H Belle; Adrian M Di Bisceglie; Jordan J Feld; William M Lee; Michael W Fried; Harry L A Janssen
Journal:  Clin Gastroenterol Hepatol       Date:  2019-02-08       Impact factor: 11.382

8.  Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Yoko Sakamoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

9.  Spontaneous seroconversion in chronic hepatitis B: role of mutations in the precore/core gene.

Authors:  E Schulte-Frohlinde; G R Foster
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

10.  Hepatitis B virus replication in patients with chronic liver diseases.

Authors:  B M Gandhi; M Irshad; S K Acharya; Y K Joshi; B N Tandon
Journal:  Gastroenterol Jpn       Date:  1990-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.